Literature DB >> 26948357

Complications from radiotherapy.

Frédéric Dhermain1, Igor J Barani2.   

Abstract

Radiotherapy (RT) of the brain is associated with significant stigma in the neuro-oncology community. This is primarily because of the potentially severe complications with which it may be associated. These complications, especially in subacute and latent settings, are often unpredictable, potentially progressive, and irreversible. The onset of complications may start from the first fraction of 2 Gy, continuing over several months after end of RT with persistent drowsiness and apathy. It may also extend over many years with progressive onset of neurocognitive impairments such as memory decline, and diminished focus/attention. For long-term survivors, such as young patients irradiated for a favorable low-grade glioma, quality of life can be seriously impacted by RT. It is essential, as in the pediatric field, to propose patient-specific regimens from the very outset of therapy. The use of molecular biomarkers to better predict survival, control of comorbidities along with judicious use of medications such as steroids and antiepileptics, improved targeting with the help of modern imaging and RT techniques, modulation of the dose, and fractionation aimed at limiting integral dose to the healthy brain all have the potential to minimize treatment-related complications while maintaining the therapeutic efficacy for which RT is known. Sparing "radiosensitive" areas such as hippocampi could have a modest but measurable impact with regard to cognitive preservation, an effect that can possibly be enhanced when used in conjunction with memantine and/or donepezil.
© 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  cerebrovascular disease; conformal radiotherapy; drugs; leukoencephalopathy; neurocognition; quality of life; radionecrosis; radiosurgery; rehabilitation

Mesh:

Year:  2016        PMID: 26948357     DOI: 10.1016/B978-0-12-802997-8.00013-X

Source DB:  PubMed          Journal:  Handb Clin Neurol        ISSN: 0072-9752


  5 in total

1.  Postsurgical Approaches in Low-Grade Oligodendroglioma: Is Chemotherapy Alone Still an Option?

Authors:  Enrico Franceschi; Alicia Tosoni; Dario De Biase; Giuseppe Lamberti; Daniela Danieli; Stefano Pizzolitto; Elena Zunarelli; Michela Visani; Enrico Di Oto; Antonella Mura; Santino Minichillo; Chiara Scafati; Sofia Asioli; Alexandro Paccapelo; Stefania Bartolini; Alba A Brandes
Journal:  Oncologist       Date:  2019-02-18

Review 2.  Glioma-Targeted Therapeutics: Computer-Aided Drug Design Prospective.

Authors:  Preantha Poonan; Clement Agoni; Mahmoud A A Ibrahim; Mahmoud E S Soliman
Journal:  Protein J       Date:  2021-09-29       Impact factor: 2.371

3.  Long-term neurocognitive and other side effects of radiotherapy, with or without chemotherapy, for glioma.

Authors:  Theresa A Lawrie; David Gillespie; Therese Dowswell; Jonathan Evans; Sara Erridge; Luke Vale; Ashleigh Kernohan; Robin Grant
Journal:  Cochrane Database Syst Rev       Date:  2019-08-05

Review 4.  Central nervous system metastases and oligoprogression during treatment with tyrosine kinase inhibitors in oncogene-addicted non-small cell lung cancer: how to treat and when?

Authors:  Janna Josephus Anna Oda Schoenmaekers; Marthe Sentijna Paats; Anne-Marie Clasina Dingemans; Lizza Elisabeth Lucia Hendriks
Journal:  Transl Lung Cancer Res       Date:  2020-12

Review 5.  IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment.

Authors:  Lidia Gatto; Enrico Franceschi; Alicia Tosoni; Vincenzo Di Nunno; Ilaria Maggio; Raffaele Lodi; Alba Ariela Brandes
Journal:  Mol Diagn Ther       Date:  2021-06-07       Impact factor: 4.476

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.